Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30979296 | 1.00 | PARP1 (0.47) | PARP1HDAC1GPR119HSD11B1F13A1 | |
| SCHEMBL31514777 | 0.90 | HDAC1 (0.45) | PARP1HDAC1GPR119HSD11B1F13A1 | |
| SCHEMBL31514813 | 0.90 | HDAC1 (0.45) | PARP1HDAC1GPR119HSD11B1F13A1 | |
| SCHEMBL31514778 | 0.84 | HDAC1 (0.45) | PARP1HDAC1GPR119HSD11B1GRM2 | |
| SCHEMBL31474312 | 0.81 | JAK1 (0.43) | PARP1HDAC1GPR119SPRBACE1 | |
| SCHEMBL28869895 | 0.80 | HDAC1 (0.50) | PARP1HDAC1GPR119HSD11B1F13A1 | |
| SCHEMBL31514674 | 0.78 | PARP1 (0.46) | PARP1HDAC1GPR119HSD11B1F13A1 | |
| SCHEMBL31514688 | 0.78 | PARP1 (0.46) | PARP1HDAC1GPR119HSD11B1F13A1 | |
| SCHEMBL22912731 | 0.75 | BACE1 (0.52) | PARP1BACE1 | |
| SCHEMBL30212537 | 0.75 | BACE1 (0.52) | PARP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4534533-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | PARP1, PARP8, PARP11 | PARP1 1/4885HDAC1 227/4885GPR119 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.